A Phase 3 interventional study of VEGF Trap-Eye 2.0mg and Sham in Macular Edema Secondary to Central Retinal Vein Occlusion, sponsored by Regeneron Pharmaceuticals. Completed at 61 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-05-27.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies testing aflibercept in Macular Edema — 1 open to participants now, 3 under way, 1 of them phase 3. aflibercept · Macular Edema.
Among the 53 studies testing aflibercept in Macular Edema, this one is the 11th largest by enrollment, is one of 2 that started in 2009, is one of 11 in phase 3, and was the 3rd registered.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
Browse Macular Edema studies →1 of the 53 studies testing aflibercept in Macular Edema is open now, in 1 country. Recruiting first, the newest first:
CMH Multan Institute of Medical Sciences · Sites in Pakistan
Ages 30–60
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 12 · Phase 4 26
First in 2006; this study’s year is marked. 2 started in 2009.
This study's enrollment of 189 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 49 across the 53 interventional studies. Of the 36 that completed or were terminated, 18 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 53 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 7 studies filed under Macular Edema — fewer than ten, so there is no comparison to draw.
1 of the studies testing aflibercept in Macular Edema that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02645266McMaster UniversityMean Visual Acuity Changes Following Five Injections of Aflibercept | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 53 studies testing aflibercept in Macular Edema, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 3 study to determine the efficacy of VEGF Trap-Eye injected into the eye on vision function in subjects with macular edema as a consequence of central retinal vein occlusion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Monthly IVT injection of VEGF Trap-Eye 2.0 mg until Week 24 Primary Endpoint
Biological: VEGF Trap-Eye 2.0mg
Monthly Sham IVT injection until Week 24 Primary Endpoint
Drug: Sham
Monthly intravitreal injection out to the Week 24 Primary endpoint
Monthly sham intravitreal injection out to Week 24 Primary Endpoint
Percentage of Participants Who Gained at Least 15 Letters in BCVA at Week 24 as Measured by ETDRS Letter Score
Percentage values indicate the number of subjects in each arm who were able to read an additional 15 letters or more at Week 24 compared to baseline. Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 24 letters (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning.
Time frame: Baseline and at Week 24
Change From Baseline in BCVA as Measured by ETDRS Letter Score at Week 24 - Last Observation Carried Forward (LOCF)
Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 24 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning.
Time frame: Baseline and at Week 24
Change From Baseline in Central Retinal Thickness (CRT) at Week 24 - LOCF
Time frame: Baseline and at Week 24
Percentage of Participants Progressing to Any of the Following: Anterior Segment Neovascularization, New Vessels of the Disc (NVD) or New Vessels Elsewhere (NVE) During the First 24 Weeks
Time frame: Baseline to Week 24
Change From Baseline in the NEI VFQ-25 in Total Score at Week 24 (LOCF)
The NEI VFQ-25 assesses visual function and quality of life. Total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales which are all scored from 0-100. To reach the overall composite score, each sub-scale score is averaged in order to give each sub-scale equal weight.
Time frame: Baseline and at Week 24
The study was conducted at 55 study centers in the United States, Canada, Columbia, India, and Israel. The recruitment period occurred between 08 Jul 2009 and 29 Apr 2010.
| Milestone | Intravitreal Aflibercept Injection (EYLEA, VEGF Trap-Eye) | Sham Treatment |
|---|---|---|
| Started | 115 | 74 |
| Participants received treatment | 114 | 74 |
| Full analysis set (fas) population | 114 | 73 |
| Completed | 110 | 60 |
| Not completed | 5 | 14 |
| Withdrew: Adverse event | 0 | 3 |
| Withdrew: Death | 0 | 2 |
| Withdrew: Withdrawal by subject | 3 | 1 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Lack of efficacy | 0 | 4 |
| Withdrew: Other | 1 | 1 |
Percentage values indicate the number of subjects in each arm who were able to read an additional 15 letters or more at Week 24 compared to baseline. Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 24 letters (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning.
| percentage of participants | Intravitreal Aflibercept Injection (EYLEA, VEGF Trap-Eye) | Sham Treatment |
|---|---|---|
| Percentage of Participants Who Gained at Least 15 Letters in BCVA at Week 24 as Measured by ETDRS Letter Score | 64 | 9 |
Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 24 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning.
| letters correctly read | Intravitreal Aflibercept Injection (EYLEA, VEGF Trap-Eye) | Sham Treatment |
|---|---|---|
| Change From Baseline in BCVA as Measured by ETDRS Letter Score at Week 24 - Last Observation Carried Forward (LOCF) | 17.3 ± 12.78 | -4.0 ± 17.96 |
| microns | Intravitreal Aflibercept Injection (EYLEA, VEGF Trap-Eye) | Sham Treatment |
|---|---|---|
| Change From Baseline in Central Retinal Thickness (CRT) at Week 24 - LOCF | -457.2 ± 238.21 | -144.8 ± 291.07 |
| percentage of participants | Intravitreal Aflibercept Injection (EYLEA, VEGF Trap-Eye) | Sham Treatment |
|---|---|---|
| Any neovascularization | 0 | 6.8 |
| Anterior segment neovascularization | 0 | 6.8 |
| Neovascularization of the optic disc (NVD) | 0 | 0 |
| Neovascularization elsewhere in the fundus (NVE) | 0 | 0 |
The NEI VFQ-25 assesses visual function and quality of life. Total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales which are all scored from 0-100. To reach the overall composite score, each sub-scale score is averaged in order to give each sub-scale equal weight.
| scores on a scale | Intravitreal Aflibercept Injection (EYLEA, VEGF Trap-Eye) | Sham Treatment |
|---|---|---|
| Change From Baseline in the NEI VFQ-25 in Total Score at Week 24 (LOCF) | 7.2 ± 12.11 | 0.8 ± 9.79 |
Collected over Baseline to Week 24; Week 24 to Week 100. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Intravitreal Aflibercept Injection (IAI) (Baseline to Week 24) | — | 6/114 (5.3%) | 57/114 (50%) |
| Sham Treatment (Baseline to Week 24) | — | 6/74 (8.1%) | 34/74 (45.9%) |
| IAI to IAI (Week 24 to Week 100) | — | 20/110 (18.2%) | 76/110 (69.1%) |
| Sham Treatment to IAI (Week 24 to Week 100) | — | 14/60 (23.3%) | 50/60 (83.3%) |
| Event | Intravitreal Aflibercept Injection (IAI) (Baseline to Week 24) | Sham Treatment (Baseline to Week 24) | IAI to IAI (Week 24 to Week 100) | Sham Treatment to IAI (Week 24 to Week 100) |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/114 | 1/74 | 0/110 | 3/60 |
| Renal failure acuteRenal and urinary disorders | 0/114 | 0/74 | 1/110 | 2/60 |
| GlaucomaEye disorders | 0/114 | 2/74 | 0/110 | 1/60 |
| Iris neovascularisationEye disorders | 0/114 | 2/74 | 0/110 | 0/60 |
| Cystoid macular oedemaEye disorders | 0/114 | 0/74 | 2/110 | 0/60 |
| Inguinal herniaGastrointestinal disorders | 0/114 | 0/74 | 2/110 | 0/60 |
| Coronary artery stenosisCardiac disorders | 0/114 | 0/74 | 2/110 | 0/60 |
| Urinary tract infectionInfections and infestations | 0/114 | 0/74 | 2/110 | 0/60 |
| AnaemiaBlood and lymphatic system disorders | 1/114 | 0/74 | 0/110 | 1/60 |
| NeutropeniaBlood and lymphatic system disorders | 0/114 | 0/74 | 0/110 | 1/60 |
| Event | Intravitreal Aflibercept Injection (IAI) (Baseline to Week 24) | Sham Treatment (Baseline to Week 24) | IAI to IAI (Week 24 to Week 100) | Sham Treatment to IAI (Week 24 to Week 100) |
|---|---|---|---|---|
| Visual acuity reducedEye disorders | 7/114 | 12/74 | 27/110 | 8/60 |
| Retinal pigment epitheliopathyEye disorders | 0/114 | 0/74 | 0/110 | 12/60 |
| Macular oedemaEye disorders | 0/114 | 0/74 | 20/110 | 0/60 |
| HypertensionVascular disorders | 10/114 | 4/74 | 13/110 | 9/60 |
| Eye painEye disorders | 16/114 | 4/74 | 9/110 | 4/60 |
| Cystoid macular oedemaEye disorders | 0/114 | 0/74 | 14/110 | 4/60 |
| MaculopathyEye disorders | 10/114 | 0/74 | 6/110 | 0/60 |
| Optic disc vascular disorderEye disorders | 8/114 | 0/74 | 6/110 | 5/60 |
| Retinal exudatesEye disorders | 7/114 | 0/74 | 0/110 | 5/60 |
| Protein urine presentInvestigations | 0/114 | 0/74 | 0/110 | 5/60 |
| Age Continuous(years) | Intravitreal Aflibercept Injection (EYLEA, VEGF Trap-Eye) | Sham Treatment | Total |
|---|---|---|---|
| Mean | 65.5 ± 13.57 | 67.5 ± 14.22 | 66.3 ± 13.83 |
| Sex: Female, Male(Participants) | Intravitreal Aflibercept Injection (EYLEA, VEGF Trap-Eye) | Sham Treatment | Total |
|---|---|---|---|
| Female | 45 | 35 | 80 |
| Male | 69 | 39 | 108 |
| Ethnicity (NIH/OMB)(Participants) | Intravitreal Aflibercept Injection (EYLEA, VEGF Trap-Eye) | Sham Treatment | Total |
|---|---|---|---|
| Hispanic or Latino | 18 | 12 | 30 |
| Not Hispanic or Latino | 96 | 62 | 158 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Intravitreal Aflibercept Injection (EYLEA, VEGF Trap-Eye) | Sham Treatment | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 2 |
| Asian | 7 | 2 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 5 | 5 | 10 |
| White | 88 | 60 | 148 |
| More than one race | 12 | 6 | 18 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Baseline Retinal Thickness by Optical Coherence Tomography (OCT)(microns) | Intravitreal Aflibercept Injection (EYLEA, VEGF Trap-Eye) | Sham Treatment | Total |
|---|---|---|---|
| Mean | 661.7 ± 237.37 | 678.4 ± 248.66 | 668.1 ± 241.23 |
| Baseline National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score(scores on a scale) | Intravitreal Aflibercept Injection (EYLEA, VEGF Trap-Eye) | Sham Treatment | Total |
|---|---|---|---|
| Mean | 77.67 ± 15.96 | 78.01 ± 16.26 | 77.81 ± 16.04 |
| Baseline Intraocular Pressure(millimeters of mercury (mmHg)) | Intravitreal Aflibercept Injection (EYLEA, VEGF Trap-Eye) | Sham Treatment | Total |
|---|---|---|---|
| Mean | 15.1 ± 3.26 | 15.0 ± 2.83 | 15.1 ± 3.09 |
| Number of Participants with Retinal Perfusion at Baseline(participants) | Intravitreal Aflibercept Injection (EYLEA, VEGF Trap-Eye) | Sham Treatment | Total |
|---|---|---|---|
| Perfused | 77 | 50 | 127 |
| Non-Perfused | 17 | 12 | 29 |
| Indeterminate | 20 | 12 | 32 |
2 further baseline measures are reported on the registry.
The record gives a start of Jul 2009, a primary completion of Oct 2010 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.
Results were first posted in May 2013, 2 years 7 months after primary completion. A results delay was requested in May 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept